SCHEMBL25819589

SCHEMBL25819589

CC(C)(C)OC(=O)NC1CCN(C2CN(C(=O)OCc3ccccc3)C2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
PDE4B Q07343 1/20 0.51
KCNA3 P22001 1/20 0.48
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSK P43235 1/20 0.47
MEN1 O00255 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HSD11B1 P28845 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
DPP4 P27487 2/20 0.45
DPP7 Q9UHL4 2/20 0.45
CYP2C19 P33261 1/20 0.45
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25935575 0.94 KMT2A (0.50) KMT2AL3MBTL1PDE4BKCNA3CTSL
SCHEMBL2744899 0.92 KMT2A (0.53) KMT2AL3MBTL1PDE4BKCNA3MEN1
SCHEMBL22234346 0.91 KMT2A (0.52) KMT2AL3MBTL1PDE4BCTSLCTSB
SCHEMBL951538 0.89 KMT2A (0.59) KMT2AL3MBTL1PDE4BKCNA3MEN1
SCHEMBL28355974 0.88 SMN1; SMN2 (0.50) KMT2AL3MBTL1PDE4BCTSLCTSB
SCHEMBL28355973 0.88 SMN1; SMN2 (0.50) KMT2AL3MBTL1PDE4BCTSLCTSB
SCHEMBL118369 0.88 KMT2A (0.52) KMT2AL3MBTL1PDE4BKCNA3MEN1
SCHEMBL27225212 0.88 KMT2A (0.52) KMT2AL3MBTL1PDE4BKCNA3MEN1
SCHEMBL26661801 0.88 KMT2A (0.52) KMT2AL3MBTL1PDE4BKCNA3MEN1
SCHEMBL1971844 0.87 HSD11B1 (0.59) KMT2AL3MBTL1PDE4BKCNA3CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658658-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2025-12-10 EP disclosed
WO-2024162828-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2024-08-08 WO disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 KMT2A 1840/4885L3MBTL1 964/4885PDE4B 3120/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 KMT2A 1115/4885L3MBTL1 2040/4885PDE4B 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.